← Leaderboards
Christopher C Porter
University Of Colorado Denver
$2,117,025
Attributed
$2,117,025
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $358.5K · FY2009–17$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$2,117,025 · 2
By mechanism
R01$1,575,837 · 1
R21$541,188 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Terry J. Fry$3,169,598
- Natalie Rose Davidson$699,191
- Matthew Witkowski$1,035,186
Others in their field
Top investigators on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Dennis R. Burton · Scripps Research Institute$257,157,696
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barton F Haynes · Duke University$186,001,832
- David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
- Reisa A. Sperling · Banner Health$137,047,788
Research focus
Pre-ClinicalClinical TrialsResistanceLeukemiaIn VivoCellsPharmaceutical PreparationsMouse ModelTranslationsXenograft ProcedurePublic Health RelevanceFailure (Biologic Function)AnthracyclinesBlast CellCombinatorialBiopsy SpecimenBiological MarkersCombination Drug TherapyCombined Modality TherapyCell DeathCell Cycle CheckpointChemotherapyCell KillingCdc2 Protein Kinase
Grant awards (8)
Validation and Development of WEE1 as a therapeutic target in AML$323,700
R01 · FY2017 · CA · contact PI
Validation and Development of WEE1 as a therapeutic target in AML$316,213
R01 · FY2016 · CA · contact PI
Validation and Development of WEE1 as a therapeutic target in AML$316,050
R01 · FY2015 · CA · contact PI
Validation and Development of WEE1 as a therapeutic target in AML$305,619
R01 · FY2014 · CA · contact PI
Validation and Development of WEE1 as a therapeutic target in AML$314,255
R01 · FY2013 · CA · contact PI
Testing the safety and efficacy of inhibitory RNA mediated purine analog resistan$182,652
R21 · FY2010 · HL · contact PI
Testing the safety and efficacy of inhibitory RNA mediated purine analog resistan$183,451
R21 · FY2009 · HL · contact PI
Testing the safety and efficacy of inhibitory RNA mediated purine analog resistan$175,085
R21 · FY2009 · HL · contact PI